Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. (Q40480144)

20 September 2017

title

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. (English)

1 reference

20 September 2017

0 references

Marcelo Wolff

6

0 references

Sean Emery

Sean Emery

13

0 references

Janaki Amin

Janaki Amin

12

0 references

Robin Wood

4

Robin Wood

1 reference

20 September 2017

Mark A Boyd

1

0 references

Kiat Ruxrungtham

7

Kiat Ruxrungtham

1 reference

20 September 2017

3

Jean-Michel Molina

1 reference

20 September 2017

Cecilia L Moore

2

1 reference

20 September 2017

Juan S Madero

5

1 reference

20 September 2017

Marcelo Losso

8

1 reference

20 September 2017

Boris Renjifo

9

1 reference

20 September 2017

Hedy Teppler

10

1 reference

20 September 2017

Anthony D Kelleher

11

1 reference

20 September 2017

David A Cooper

14

1 reference

20 September 2017

SECOND-LINE study group

15

1 reference

20 September 2017

publication date

20 January 2015

1 reference

20 September 2017

1 reference

20 September 2017

volume

2

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

e42-51

1 reference

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Assessment of second-line antiretroviral regimens for HIV therapy in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Implications of antiretroviral resistance on viral fitness

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the ran

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

HIV RNA and genotype in resource-limited settings: can we do better?

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2814%2900061-7

7 January 2021

10.1016/S2352-3018(14)00061-7

Identifiers

DOI

1 reference

20 September 2017

1 reference